Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 266Lung Neoplasms 102Adenocarcinoma of Lung 28Mesothelioma, Malignant 24Mesothelioma 22Neoplasms 18Meningeal Carcinomatosis 18Brain Neoplasms 16Head and Neck Neoplasms 14Neoplasm Metastasis 13Ovarian Neoplasms 9NSCLC 9Colorectal Neoplasms 8Adenocarcinoma, Bronchiolo-Alveolar 8Breast Neoplasms 7Recurrence 6Carcinoma, Transitional Cell 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Lymphoma 5Esophageal Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 4Sarcoma 4Non-squamous Non-small Cell Lung Cancer 4Non-small Cell Lung Cancer Metastatic 4Fallopian Tube Neoplasms 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3

Interventions

toripalimab 3Injections 2Surveys and Questionnaires 1Pemetrexed 1Paclitaxel 1Etoposide 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Lung Cancer × Pemetrexed × Clear all
NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡